Skip to content
drillr.ai
Sign up

VRTX

Vertex Pharmaceuticals Incorporated

NASDAQ · Healthcare · Biotechnology · US

$546.12
−2.12%
Ask drillr

  • Sep 1, 2026, 20:28 UTC

    Vertex Pharmaceuticals announced that Jonathan Poole will become Executive Vice President and Chief Financial Officer, effective January 1, 2027, succeeding Charles F. Wagner, Jr., who will transition to Executive Vice President and Chief Operating & Financial Officer.

  • Aug 23, 2026, 09:03 UTC

    EP Wealth Advisors LLC acquired a new stake in Vertex Pharmaceuticals Incorporated during the second quarter, purchasing 9,027 shares valued at approximately $4,484,000.

    Source:

  • Aug 20, 2026, 07:18 UTC

    AssuredPartners Investment Advisors LLC acquired a new stake in Vertex Pharmaceuticals Incorporated, purchasing 4,147 shares valued at approximately $2.06 million, as disclosed in a recent SEC filing.

    Source:

  • Aug 10, 2026, 12:03 UTC

    Sionna Therapeutics announced that its experimental cystic fibrosis pill SION-719 failed to show benefit in a Phase 2 trial when added to Vertex Pharmaceuticals' Trikafta, and the company will not advance it as an add-on therapy.

    Source:

  • Jul 29, 2026, 21:00 UTC

    Latigo Biotherapeutics published positive Phase 2 trial data for its experimental pain drug LTG-001, a potential rival to Vertex's Journavx, on July 29, 2026.

    Source:

  • Jul 29, 2026, 11:00 UTC

    AbCellera announced a collaboration with Vertex to discover multispecific T-cell engagers for autoimmune diseases and other conditions.

    Source:

  • Jul 7, 2026, 00:00 UTC

    Vertex Pharmaceuticals signed a merger agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, expected to close in Q3 2026.

    Source:

  • Jul 2, 2026, 15:46 UTC

    Vertex Pharmaceuticals received FDA approval to expand the use of Casgevy in patients aged two and older with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

    Source:

  • Jun 3, 2026, 12:00 UTC

    The FDA granted 510(k) clearance for the BD BACTEC FXI Culture System, a bloodstream infection diagnostic device.

    Source:

  • Jun 2, 2026, 16:51 UTC

    NeuroPace (NPCE) received FDA approval for its AI-powered ECoG Assistant for epilepsy.

    Source:

  • Jun 2, 2026, 16:10 UTC

    The FDA accepted Vertex's Biologics License Application for povetacicept in adults with IgA nephropathy, with a decision due in November 2026.

    Source: